Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Galena Biopharma (NASDAQ: GALE ) , a biopharmaceutical company focused on developing cancer therapies, advanced as much as 13% following the announcement of its first official product launch -- Abstral, for the management of breakthrough pain in patients with cancer.
So what: As a refresher, Galena acquired Abstral sublingual tablets from Orexo in March for sale within the United States. Abstral is approved as a breakthrough cancer pain treatment in patients in the U.S. and in Europe; it is most often prescribed as a therapy measure in cases of advanced breast cancer and for patients who have solid tumors. Peak sales estimates in the U.S. vary wildly but are generally around $50 million, compared to the $54 million in sales that Abstral delivered in Europe last year.
Now what: The commercial launch of Abstral in the U.S. today is certainly good news by adding revenue to reduce Galena's cash burn rate. But all eyes are really on the company's cancer vaccine NeuVax, which is currently in late-stage trials for HER2-targeted breast cancer. Abstral alone likely doesn't offer Galena enough to make it to profitability, so the company will likely need positive results from NeuVax if it hopes to continue heading higher. One catch: We're about three years from getting those phase 3 results. I would personally prefer to wait on the sidelines until we have those concrete results rather than chase this stock higher or lower on news like we're witnessing today.
The two revolutionary biotechs you should be watching instead
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.